Compare FDC with Similar Stocks
Dashboard
The company is Net-Debt Free
Poor long term growth as Operating profit has grown by an annual rate -1.62% of over the last 5 years
Positive results in Jun 26
With ROE of 12, it has a Fair valuation with a 2.4 Price to Book Value
Falling Participation by Institutional Investors
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 6,178 Cr (Small Cap)
20.00
37
1.29%
-0.20
11.98%
2.54
Total Returns (Price + Dividend) 
Latest dividend: 5 per share ex-dividend date: Feb-11-2026
Risk Adjusted Returns v/s 
Returns Beta
News
Are FDC Ltd latest results good or bad?
FDC Ltd's latest financial results for Q1 FY27 reveal a company experiencing notable operational momentum in the short term, with net profit reaching ₹132.49 crores, reflecting a 28.13% increase compared to the previous quarter. Revenue also demonstrated growth, climbing to ₹667.69 crores, which represents a 14.18% sequential rise. The operating margin, excluding other income, improved to 21.42%, indicating enhanced cost management and operational efficiency. Despite these positive quarterly results, the year-on-year revenue growth moderated to 2.97%, suggesting challenges in sustaining momentum compared to the same period last year. The company's net profit margin improved to 19.84%, driven by operational leverage and a favorable tax rate, which is a significant achievement compared to previous quarters. However, FDC's historical performance shows considerable margin volatility, with operating margins fl...
Read full news article
FDC Ltd Valuation Shifts to Fair: A Detailed Analysis of Price Attractiveness
FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with a recent upgrade in its Mojo Grade from Sell to Hold, reflects evolving market perceptions and presents a nuanced picture for investors assessing price attractiveness against sector peers and historical benchmarks.
Read full news article
FDC Ltd Q1 FY27: Stellar Profit Surge Masks Margin Volatility Concerns
FDC Ltd., a fully integrated research-oriented pharmaceutical company specialising in formulations and active pharmaceutical ingredients, reported a robust 28.13% quarter-on-quarter surge in net profit to ₹132.49 crores for Q1 FY27, up from ₹103.40 crores in Q4 FY26. On a year-on-year basis, the company posted a 9.17% increase from ₹121.36 crores in Q1 FY26. Despite the impressive profit growth, the stock tumbled 3.85% to ₹387.50 on August 05, 2026, reflecting investor concerns over historical margin inconsistency and persistent underperformance against benchmark indices.
Read full news article Announcements 
FDC Limited - Clarification - Financial Results
14-Nov-2019 | Source : NSEFDC Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
FDC Limited - Updates
18-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Acquisition of Registered Trademark/ Brand "ENTEROPLUS" from GlaxoSmithKline Pharmaceuticals Limited (GSK)'.
FDC Limited - Updates
16-Oct-2019 | Source : NSEFDC Limited has informed the Exchange regarding 'Certificate in terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 ( said regulations ) on behalf of FDC Limited ( the Company ) for the quarter ended on September 30, 2019'.'.
Corporate Actions 
No Upcoming Board Meetings
FDC Ltd has declared 500% dividend, ex-date: 11 Feb 26
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 5 Schemes (6.25%)
Held by 74 FIIs (1.4%)
Nomita R Chandavarkar (22.67%)
Icici Prudential Smallcap Fund (2.8%)
17.64%
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
QoQ Growth in quarter ended Jun 2026 is 14.18% vs 25.84% in Mar 2026
QoQ Growth in quarter ended Jun 2026 is 28.13% vs 265.37% in Mar 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is -2.66% vs 12.65% in Sep 2024
Growth in half year ended Sep 2025 is -21.65% vs 6.33% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is -1.86% vs 9.14% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -21.96% vs -11.90% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 2.98% vs 8.50% in Mar 2025
YoY Growth in year ended Mar 2026 is 5.48% vs -12.59% in Mar 2025






